Evidence map›Paper›PMID 11293117›Full record

ReviewAdvances in immunology2001

The antiviral activity of antibodies in vitro and in vivo.

P W Parren, D R Burton

Abstract readReview
In one paragraph

Review in Advances in immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

P W ParrenDepartments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California 92037, USA.
D R Burton

Funding

HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR01AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 1992 to 2013
$5.9M
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR37AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 1995 to 2004
$2.4M
NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSESU01AI048494 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 2000 to 2004
$1.8M
ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPPL-SCID MICER01HL059727 · NHLBI · SCRIPPS RESEARCH INSTITUTE · PI BURTON, DENNIS R. · 1997 to 2001
$1.1M
ANTIBODY FC AND HIV-1 INACTIVATIONR29AI040377 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI PARREN, PAUL W · 1996 to 2000
$125k
NHLBI NIH HHS HL59727NIAID NIH HHS AI33292NIAID NIH HHS AI40377NIAID NIH HHS AI48494
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntibodies, ViralComplement System ProteinsCytotoxicity, ImmunologicHumansIntracellular FluidNeutralization TestsPhagocytosisVirus DiseasesAntibodies, ViralComplement System Proteins

Identifiers

PMID11293117
PMCPMC7131048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.